Fig. 1

Level of expression of human wt-αsyn in AAV1 icv injected mice. a, f Photomicrographs of representative brain of animals injected with AAV1-αsyn (a, b, c, and f) and AAV-venus (e, d). Human αsyn-specific antibody reveals high level of expression throughout the brain in AAV1-syn mice at 1, 3 and 6 months after injection (a, b, c respectively), whereas AAV-venus injected animal is negative (d). When using a GFP antibody, only mice injected with the AAV-venus control show a positive staining (e). g Level of expression of the transgene was assessed by western blot at all ages. Representative animals at 3 months of age show a robust expression of total αsyn in AAV1-syn group compared to AAV-venus. Antibody recognizing human and mouse αsyn was used (clone 42). h Quantification of the western blot shows αsyn level increase up to 3 fold. The data are expressed as the amount of total level of αsyn normalized to actin (*, p < 0.05) and are from 3 repeated experiments (n = 8–13) per age group per genotype). i RT-qPCR was performed to compare the level of gene expression at 3 and 6 months of age with primers specific for human or mouse αsyn. Scale bar in e = 1 mm and apply to a, b, c, d and f